Table 2.
Immunoprophylaxis for HBV Infection in Liver Transplant Recipients
| Study | Number of Patients | Strategy | Oral Agents (n)* | HBV Recurrence (%) | Median Follow-up (months) |
|---|---|---|---|---|---|
| Fung et al23 | 80 | No HBIG | ETV (80) | 18/80 (23) | 26 |
| Wadhawan et al45 | 75 | No HBIG | LAM + ADV (19) ETV (42) TDF (12) ETV + TDF (2) |
6/75 (8) | 21 |
| Degertekin et al20 | 23 | HBIG for 12 months | LAM ADV ETV TDF LAM + ADV LAM + TDF ETV + ADV TDF + ADV |
3/23 (13) | 53 |
| Nath et al37 | 14 | HBIG for 7 days | LAM + ADV | 0/14 (0) | 14 |
| Teperman et al39 | 16 | HBIG for 6 months | FTC + TDF | 0/16 (0) | 18 |
| Neff et al42 | 10 | HBIG for 7 months | LAM + ADV | 0/10 (0) | 31 |
*
The specific number of patients on each oral regimen is unknown.
ADV, adefovir; ETV, entecavir; FTC, emtricitabine; HBIG, hepatitis B immunoglobulin; HBV, hepatitis B virus; LAM, lamivudine; TDF, tenofovir.